A breakthrough study from The University of Texas MD Anderson Cancer Center has revealed that the inflammatory protein Interleukin-18, or IL-18, could be a major obstacle—and opportunity—when fighting pancreatic cancer. The research, published November 17, 2026, in the journal Gastroenterology, sheds new light on how pancreatic tumors evade immune detection, a challenge that has long hampered promising therapies in this deadly disease.

In these preclinical studies, scientists found that IL-18 fosters an environment ideal for tumor growth by raising levels of CD47, a protein essentially signaling immune cells not to attack the cancer. When IL-18 was reduced, not only did tumor growth slow, but experimental treatments targeting the commonly mutated KRAS gene became notably more effective. Survival rates in animal models increased, and the tumors’ surroundings appeared less hostile to the immune system’s efforts.

The discovery comes at a crucial time. Pancreatic cancer, described in recent systematic reviews as one of the most lethal cancers with a five-year survival rate near 13%, has resisted most immunotherapies that have transformed care for other tumor types (Sodergren et al., 2020). Even advanced treatments leveraging immune checkpoint inhibitors, such as pembrolizumab or nivolumab, have yielded underwhelming results, with response rates frequently below 5% (Gong et al., 2018; Sohrabi et al., 2026).

Importantly, the new research shows that attacking tumors with KRAS inhibitors alone may backfire, as the treatment appears to heighten IL-18 levels—potentially helping cancers resist therapy. Combining IL-18-targeted therapies with KRAS inhibitors, however, seems to amplify anti-tumor effects, at least in model systems.

Experts note that while these findings are currently limited to the laboratory, they provide a compelling rationale for clinical trials now underway or planned. Determining the safest and most effective ways to suppress IL-18 in human patients while combining it with other therapies remains a challenge, and the optimal methods to do so have yet to be fully established.

The implications of these discoveries could be far-reaching. If IL-18 targeting proves successful in humans, it may pave the way for finally overcoming pancreatic cancer’s formidable resistance to immunotherapy—a hope echoed for decades but rarely fulfilled.

For many, the promise of combination approaches suggests not just incremental progress, but a possible paradigm shift in how pancreatic cancer is treated, emphasizing adaptation to the tumor’s unique microenvironment and its molecular defenses.